Pharmac drops ethnicity and heart-risk rules for four diabetes medicines from 1 September

Updated

Written by

Reviewed by Smiths Insurance & KiwiSaver Licensed Financial Advice Provider (FSP712931)

Our editorial process

Read this article with AI:

Photo for the story: Pharmac drops ethnicity and heart-risk rules for four diabetes medicines from 1 September

One HbA1c blood test now decides who qualifies, and Pharmac expects about 14,000 more people on the medicines in the first year.

Pharmac is dropping the ethnicity and heart-risk rules for four type 2 diabetes medicines from 1 September, leaving one blood test to decide who qualifies.

The test is HbA1c, which shows average blood sugar over the past three months. If other funded diabetes medicines haven't brought it below 53 mmol/mol, a person qualifies, Pharmac said on 5 August.

The four are empagliflozin (Jardiance), empagliflozin with metformin (Jardiamet), dulaglutide (Trulicity) and liraglutide (Victoza).

All four sit behind a Special Authority, the form a doctor fills in to unlock funding. The old form asked about ethnicity, diagnosed heart disease or a five-year heart risk of 15% or more, and diabetic kidney disease. All of that goes.

Empagliflozin, alone or with metformin, still comes first. The other two follow if the doctor agrees.

About 145,000 people already take these medicines. Pharmac expects around 14,000 more in the first year and around 31,000 more within five years.

The final decision went further than the one Pharmac put out for consultation in May. That proposal was narrower: drop the ethnicity rules and lower the heart-risk threshold.

Nearly 1,900 submissions came back. Many warned that dropping the ethnicity rules would cost eligible Māori and Pacific people their access.

So Pharmac widened the plan instead.

"Everyone, including Māori and Pacific people, who would currently be able to access these medicines would be covered under these revised criteria," the decision says.

All four medicines were already state-funded before the decision, so it doesn't change what non-Pharmac drug cover from health insurers pays for.

That cover is aimed at medicines Medsafe has approved but Pharmac doesn't fund. nib describes its non-PHARMAC Plus option as cover for "Medsafe-approved, non-PHARMAC funded drugs prescribed in line with Medsafe's guidelines".

Southern Cross caps what it pays for cancer drugs in the same category.

Both wordings turn on whether Pharmac funds a medicine at all, not on whether it funds it for a particular person.

Public waiting lists and what private treatment costs are the two numbers health cover is bought against. Health insurance in New Zealand

This story is general information only. It isn't financial advice and doesn't take your circumstances, health or existing cover into account. Policy terms, conditions, exclusions and stand-down periods apply and can change. QuoteHub usually doesn't charge you for advice and may receive commission from insurers; our disclosure statement explains how we're paid.

Sources

Corrections · How we report the news

Wondering whether this affects your cover?

Book a cover review

Free, no obligation. Financial advice is provided by Craig Smith Business Services Limited, trading as Smiths Insurance & KiwiSaver, a licensed Financial Advice Provider (FSP712931). Disclosure statement

Start your free comparison

Compare panel options first. A licensed NZ adviser can then review existing cover or help with an application.

Free, no obligation. Licensed NZ advisers · Craig Smith Business Services Limited, FAP FSP712931.